Panacea Biotec Share Price
18 Nov, 2026 3:18 PM (IST)
Panacea Biotec Performance
- Today's Low
- ₹344
- Today's High
- ₹362
- 52 Week Low
- ₹292
- 52 Week High
- ₹647
- Open Price₹360
- Previous Close₹353
- Volume121,373
- 50 DMA₹360.90
- 100 DMA₹382.30
- 200 DMA₹394.40
Panacea Biotec Chart
Investment Returns
- Over 1 Month -0.1%
- Over 3 Month -13.02%
- Over 6 Month -7.01%
- Over 1 Year -7.85%
Smart Investing Starts Here Start SIP with Panacea Biotec for Steady Growth!
Panacea Biotec Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 119.6
- PEG Ratio
- 0.3
- Market Cap Cr
- 2,201
- P/B Ratio
- 2.6
- Average True Range
- 15.8
- EPS
- 3
- Dividend Yield
- 0
- MACD Signal
- 0.6
- RSI
- 51.75
- MFI
- 78.99
Latest Stock News Updates
<h3><span style="font-size:16px;"><strong>Biotechnology company Panacea Biotec announced Q2FY27 results</strong></span></h3> <p><strong>Consolidated Financial Highlights:</strong><!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--></p> <ul data-complete="true" data-hveid="CAAIDRAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="aKIYbb_1p"> <li data-complete="true" data-hveid="CAAIDRAC" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_1s"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_1u">Revenue from operations:<!--TgQPHd|||[]--></strong> In Q2FY27, consolidated revenue from operations stood at Rs 18,967 lakh, declining by 4.96% QoQ from Rs 19,957 lakh in Q1FY27 and increasing by 34.39% YoY from Rs 14,113 lakh in Q2FY26. For H1FY27, consolidated revenue from operations grew by 26.45% YoY to Rs 38,924 lakh compared to Rs 30,783 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDRAF" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_21"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_23">Total income:<!--TgQPHd|||[]--></strong> In Q2FY27, consolidated total income stood at Rs 19,627 lakh, registering a decline of 3.70% QoQ from Rs 20,381 lakh in Q1FY27 and a growth of 33.04% YoY from Rs 14,753 lakh in Q2FY26. For H1FY27, consolidated total income rose by 25.06% YoY to Rs 40,008 lakh from Rs 31,990 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDRAI" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_2a"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_2c">Profit before tax (PBT):<!--TgQPHd|||[]--></strong> In Q2FY27, consolidated PBT surged by 375.91% QoQ to Rs 1,699 lakh from Rs 357 lakh in Q1FY27, turning profitable YoY against a loss before tax of Rs 1,917 lakh in Q2FY26. For H1FY27, consolidated PBT turned positive at Rs 2,056 lakh compared to a loss before tax of Rs 1,261 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDRAL" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_2j"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_2l">Profit after tax (PAT):<!--TgQPHd|||[]--></strong> In Q2FY27, consolidated PAT jumped by 441.36% QoQ to Rs 1,191 lakh from Rs 220 lakh in Q1FY27, swinging to a profit YoY against a net loss of Rs 1,401 lakh in Q2FY26. For H1FY27, consolidated PAT stood at Rs 1,411 lakh compared to a net loss of Rs 1,005 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDRAO" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_2s"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_2u">Earnings per share (EPS):<!--TgQPHd|||[]--></strong> In Q2FY27, consolidated basic and diluted EPS rose by 400.00% QoQ to Rs 1.90 from Rs 0.38 in Q1FY27, improving YoY from a loss per share of Rs 2.27 in Q2FY26. For H1FY27, consolidated basic and diluted EPS stood at Rs 2.27 compared to a loss per share of Rs 1.62 in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <!--TgQPHd|||[]--> </ul> <p><!--TgQPHd|||[]--></p> <p><strong>Standalone Financial Highlights:</strong><!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--></p> <ul data-complete="true" data-hveid="CAAIDxAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="aKIYbb_3a"> <li data-complete="true" data-hveid="CAAIDxAC" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_3d"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_3f">Revenue from operations:<!--TgQPHd|||[]--></strong> In Q2FY27, standalone revenue from operations stood at Rs 12,669 lakh, decreasing by 5.95% QoQ from Rs 13,471 lakh in Q1FY27 and increasing by 39.51% YoY from Rs 9,081 lakh in Q2FY26. For H1FY27, standalone revenue from operations increased by 28.73% YoY to Rs 26,140 lakh from Rs 20,306 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDxAD" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_3h"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_3j">Total income:<!--TgQPHd|||[]--></strong> In Q2FY27, standalone total income stood at Rs 13,310 lakh, declining by 5.45% QoQ from Rs 14,077 lakh in Q1FY27 and rising by 40.97% YoY from Rs 9,442 lakh in Q2FY26. For H1FY27, standalone total income grew by 29.42% YoY to Rs 27,387 lakh from Rs 21,162 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDxAE" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_3l"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_3n">Profit before tax (PBT):<!--TgQPHd|||[]--></strong> In Q2FY27, standalone PBT rose by 604.00% QoQ to Rs 1,408 lakh from Rs 200 lakh in Q1FY27, turning profitable YoY against a loss before tax of Rs 2,093 lakh in Q2FY26. For H1FY27, standalone PBT turned positive at Rs 1,608 lakh compared to a loss before tax of Rs 2,977 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDxAF" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_3p"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_3r">Profit after tax (PAT):<!--TgQPHd|||[]--></strong> In Q2FY27, standalone PAT surged by 673.38% QoQ to Rs 1,075 lakh from Rs 139 lakh in Q1FY27, swinging to a profit YoY from a net loss of Rs 1,564 lakh in Q2FY26. For H1FY27, standalone PAT reached Rs 1,214 lakh compared to a net loss of Rs 2,234 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDxAG" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_3t"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_3v">Earnings per share (EPS):<!--TgQPHd|||[]--></strong> In Q2FY27, standalone basic and diluted EPS rose by 665.22% QoQ to Rs 1.76 from Rs 0.23 in Q1FY27, improving YoY from a loss per share of Rs 2.55 in Q2FY26. For H1FY27, standalone basic and diluted EPS stood at Rs 1.98 compared to a loss per share of Rs 3.65 in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <!--TgQPHd|||[]--> </ul> <p><!--TgQPHd|||[]--></p> <p><strong>Business & Segment-Wise Highlights:</strong><!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--></p> <ul data-complete="true" data-hveid="CAAIERAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="aKIYbb_47"> <li data-complete="true" data-hveid="CAAIERAC" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_4a"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_4c">Vaccines segment:<!--TgQPHd|||[]--></strong> In Q2FY27, segment revenue stood at Rs 12,422 lakh, down 7.76% QoQ from Rs 13,467 lakh in Q1FY27 and up 36.79% YoY from Rs 9,081 lakh in Q2FY26, while H1FY27 segment revenue grew by 27.49% YoY to Rs 25,889 lakh from Rs 20,306 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIERAD" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="aKIYbb_4e"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="aKIYbb_4g">Formulations segment:<!--TgQPHd|||[]--></strong> In Q2FY27, segment revenue increased by 0.85% QoQ to Rs 6,545 lakh from Rs 6,490 lakh in Q1FY27 and grew by 30.07% YoY from Rs 5,032 lakh in Q2FY26, while H1FY27 segment revenue rose by 24.42% YoY to Rs 13,035 lakh from Rs 10,477 lakh in H1FY26.</li> </ul> <p><a class="lb" href="/get-document/post/pdf/5953382/" target="_blank">Result PDF</a></p>
- Trendlyne
- 1 day 22 hours ago
Please find attached newspaper copies of the extract of statement of Unaudited Financial Results for the quarter and half year ended September 30, 2026.
- BSE India
- 2 days ago
Please find attached Unaudited Financial Results for quarter and half year ended September 30, 2026
- BSE India
- 3 days 18 hours ago
Panacea Biotec Financials
Panacea Biotec Technicals
EMA & SMA
- Bearish Moving Average 6
- Bullish Moving Average 10
- 20 Day
- ₹347.90
- 50 Day
- ₹360.90
- 100 Day
- ₹382.30
- 200 Day
- ₹394.40
Resistance and Support
- R3 377.60
- R2 369.30
- R1 361.00
- S1 344.40
- S2 336.10
- S3 327.80
Panacea Biotec Corporate Actions - Bonus, Splits, Dividends
About Panacea Biotec
Panacea Biotec engaged in the business of research, development, manufacture and marketing of vaccines in India and international markets. View More- NSE Symbol
- PANACEABIO
- BSE Symbol
- 531349
- ISIN
- INE922B01023
Similar Stocks to Panacea Biotec
Popular Stocks
Panacea Biotec FAQs
Panacea Biotec share price is ₹359 As on 18 November, 2026 | 15:06
The Market Cap of Panacea Biotec is ₹2201 Cr As on 18 November, 2026 | 15:06
The P/E ratio of Panacea Biotec is 119.6 As on 18 November, 2026 | 15:06
The PB ratio of Panacea Biotec is 2.6 As on 18 November, 2026 | 15:06
The 52 week High & Low of Panacea Biotec is ₹647/₹292.4 respectively As on 18 November, 2026 | 15:06
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.